Emerging drug targets for HIV therapy: A review

International Journal of ChemTech Research

Volumn 2, Issue 2, 2010, Pages

  Nawale, Swapnil ^a   Neve, Shashank ^a   Kadam, V J ^a   Toraskar, M P ^a  

^a BHARATI VIDYAPEETH S COLLEGE OF PHARMACY   (India)

Author keywords

Anti retroviral therapy; DHS; HIV; References

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; 8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; ENFUVIRTIDE; GLYCOPROTEIN GP 120; IBALIZUMAB; KRH 2731; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PLERIXAFOR; PRO 140; PROTEIN DISULFIDE ISOMERASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VICRIVIROC;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; DISULFIDE BOND; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; MACROPHAGE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS INHIBITION;

EID: 77954733567     PISSN: None     EISSN: 09744290     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Reeves J D, Piefer A J, Emerging drug targets for antiretroviral therapy. Drugs 2005, 65, 1747-1766.
2. Esté, J A, Telenti A, HIV entry inhibitors. Lancet 2007, 370, 81-88.
3. Agrawal L, Lu X, Jin Q, Alkhatib G, Anti-HIV therapy: current and future directions. Curr. Pharm. Des. 2005, 1, 2031-2055.
4. Cooley L A, Lewin S R, HIV-1 cell entry and advances in viral entry inhibitor therapy. J. Clin. Virol. 2003, 26, 121-132.
5. Ryser H.J, Flückiger R, Progress in targeting HIV-1 entry. Drug Discov. Today. 2005, 10, 1085-1094.
6. Carr A, Toxicity of antiretroviral therapy and implications for drug development.Nat. Rev. Drug Discov. 2003, 2, 624-634.
7. Emerman M, Malim M H, HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 1998, 280, 1880-1884.
8. Karn J, Tackling tat. J. Mol. Biol. 1999, 293, 235-254.
9. Hauber I, Bevec D, Heukeshoven, J.; Krätzer, F.; Horn, F.; Choidas, A.; Harrer, T.; Hauber, J. Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. J. Clin. Invest. 2005, 115, 76-85.
10. Schnell M J, Johnson J E, Buonocore L, Rose J K, Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 1997, 90, 849-857.
11. Ferrantelli F, Cafaro A, Ensoli B, Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Curr. Opin. Biotechnol. 2004, 15, 543-556.
12. Lu W, Arraes L C, Ferreira W T, Andrieu J M, Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 2004, 10, 1359-1365.